Clinical Trial Update: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes [Phase 4]

View source ↗

Summary

The Phase 4 INHALE-3 trial evaluating Afrezza in combination with insulin degludec versus usual care for adults with Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)
• Tresiba (insulin degludec)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes Mellitus, Type 1 | Phase 4 | Status: COMPLETED